King, K. Y. & Goodell, M. A. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat. Rev. Immunol. 11, 685–692 (2011).
Pietras, E. M. et al. Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions. Cell Stem Cell 17, 35–46 (2015).
Kovtonyuk, L. V., Fritsch, K., Feng, X., Manz, M. G. & Takizawa, H. Inflamm-aging of hematopoiesis, hematopoietic stem cells, and the bone marrow microenvironment. Front. Immunol. 7, 502 (2016).
Jaiswal, S. & Ebert, B. L. Clonal hematopoiesis in human aging and disease. Science 366, eaan4673 (2019).
Yura, Y., Sano, S. & Walsh, K. Clonal hematopoiesis: a new step linking inflammation to heart failure. JACC Basic Transl. Sci. 5, 196–207 (2020).
Chavakis, T., Wielockx, B. & Hajishengallis, G. Inflammatory modulation of hematopoiesis: linking trained immunity and clonal hematopoiesis with chronic disorders. Annu. Rev. Physiol. 84, 183–207 (2022).
Jaiswal, S. et al. Age-related clonal hematopoiesis associated with adverse outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Genovese, G. et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N. Engl. J. Med. 371, 2477–2487 (2014). Jaiswal et al. (2014) and Genovese et al. (2014) pioneered whole-exome sequencing studies linking age-related clonal expansion of CHIP-mutant HSCs to increased risk of haematological malignancies and other disorders, including cardiovascular disease.
Fuster, J. J. et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science 355, 842–847 (2017). This research is one of the first experimental studies to delve into the mechanisms that explain the association of TET2-driven CHIP with atherosclerosis; the authors have shown that Tet2-mutant macrophages release increased levels of IL-1β and their effect on atherosclerosis can be negated by inhibition of the NLRP3 inflammasome.
Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol. 4, 25–33 (2019).
Lee, M. K. S. et al. Interplay between clonal hematopoiesis of indeterminate potential and metabolism. Trends Endocrinol. Metab. 31, 525–535 (2020).
Oren, O., Small, A. M. & Libby, P. Clonal hematopoiesis and atherosclerosis. J. Clin. Invest. 134, e180066 (2024).
Vlasschaert, C. et al. Clonal hematopoiesis of indeterminate potential is associated with acute kidney injury. Nat. Med. 30, 810–817 (2024).
Miller, P. G. et al. Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood 139, 357–368 (2022).
Wong, W. J. et al. Clonal haematopoiesis and risk of chronic liver disease. Nature 616, 747–754 (2023).
Dawoud, A. A. Z., Gilbert, R. D., Tapper, W. J. & Cross, N. C. P. Clonal myelopoiesis promotes adverse outcomes in chronic kidney disease. Leukemia 36, 507–515 (2022).
Tobias, D. K. et al. Clonal hematopoiesis of indeterminate potential (CHIP) and incident type 2 diabetes risk. Diabetes Care 46, 1978–1985 (2023).
Kim, P. G. et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J. Exp. Med. 218, e20211872 (2021).
Wang, H. et al. Clonal hematopoiesis driven by mutated DNMT3A promotes inflammatory bone loss. Cell 187, 3690–3711.e19 (2024). Together with Kim et al. (2021), this research dissects mechanisms whereby DNMT3A-driven CHIP can aggravate distinct bone loss disorders and suggests that CHIP is a common mechanistic basis for comorbidities in old age.
Hiitola, E. et al. Clonal hematopoiesis is associated with distinct rheumatoid arthritis phenotypes. Sci. Adv. 11, eadt9846 (2025).
Wu, H., Wei, J., Yu, Y., Wang, N. & Tan, X. Clonal hematopoiesis of indeterminate potential and the risk of autoimmune diseases. J. Intern. Med. 297, 642–656 (2025).
Schuermans, A. & Honigberg, M. C. Clonal haematopoiesis in cardiovascular disease: prognostic role and novel therapeutic target. Nat. Rev. Cardiol. 22, 845–856 (2025).
Ferrucci, L. & Fabbri, E. Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty. Nat. Rev. Cardiol. 15, 505–522 (2018).
Kovtonyuk, L. V. et al. IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice. Blood 139, 44–58 (2022). This study describes a self-sustaining loop, which links the gut microbiome with IL-1R signalling in HSCs, as a driver of haematopoietic inflammageing.
Fulop, T. et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front. Immunol. 8, 1960 (2018).
Wang, B., Han, J., Elisseeff, J. H. & Demaria, M. The senescence-associated secretory phenotype and its physiological and pathological implications. Nat. Rev. Mol. Cell Biol. 25, 958–978 (2024).
Di Micco, R., Krizhanovsky, V., Baker, D. & d’Adda di Fagagna, F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 22, 75–95 (2021).
MacNee, W., Rabinovich, R. A. & Choudhury, G. Ageing and the border between health and disease. Eur. Resp. J. 44, 1332–1352 (2014).
Salminen, A., Kaarniranta, K. & Kauppinen, A. Inflammaging: disturbed interplay between autophagy and inflammasomes. Aging 4, 166–175 (2012).
Zhang, R., Chen, H. Z. & Liu, D. P. The four layers of aging. Cell Syst. 1, 180–186 (2015).
Bana, B. & Cabreiro, F. The microbiome and aging. Ann. Rev. Genet. 53, 239–261 (2019).
Trowbridge, J. J. & Starczynowski, D. T. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J. Exp. Med. 218, e20201544 (2021).
Caiado, F. et al. Aging drives Tet2+/− clonal hematopoiesis via IL-1 signaling. Blood 141, 886–903 (2023).
Yeaton, A. et al. The impact of inflammation-induced tumor plasticity during myeloid transformation. Cancer Discov. 12, 2392–2413 (2022).
Abegunde, S. O., Buckstein, R., Wells, R. A. & Rauh, M. J. An inflammatory environment containing TNFα favors Tet2-mutant clonal hematopoiesis. Exp. Hematol. 59, 60–65 (2018).
Cai, Z. et al. Inhibition of inflammatory signaling in Tet2 mutant preleukemic cells mitigates stress-induced abnormalities and clonal hematopoiesis. Cell Stem Cell 23, 833–849.e5 (2018).
Xie, J. et al. STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation. Leukemia 37, 2457–2467 (2023).
Hormaechea-Agulla, D. et al. Chronic infection drives Dnmt3a-loss-of-function clonal hematopoiesis via IFNγ signaling. Cell Stem Cell 28, 1428–1442.e6 (2021).
Heyde, A. et al. Increased stem cell proliferation in atherosclerosis accelerates clonal hematopoiesis. Cell 184, 1348–1361.e22 (2021). On the basis of observations and mathematical modelling, this study suggests that atherosclerosis increases HSC proliferation and accelerates somatic evolution and the expansion of clones with CHIP-driver mutations.
Esai Selvan, M. et al. Clonal hematopoiesis of indeterminate potential in Crohn’s disease and ulcerative colitis. Inflamm. Bowel Dis. 31, 2123–2133 (2025).
Gutierrez-Rodrigues, F. et al. Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood 142, 244–259 (2023).
Dharan, N. J. et al. HIV is associated with an increased risk of age-related clonal hematopoiesis among older adults. Nat. Med. 27, 1006–1011 (2021).
Bick, A. G. et al. Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. Sci. Rep. 12, 577 (2022).
Ricard, L. et al. Clonal haematopoiesis is increased in early onset in systemic sclerosis. Rheumatology 59, 3499–3504 (2020).
David, C. et al. Clonal haematopoiesis of indeterminate potential and cardiovascular events in systemic lupus erythematosus (HEMATOPLUS study). Rheumatology 61, 4355–4363 (2022).
Avagyan, S. & Zon, L. I. Clonal hematopoiesis and inflammation — the perpetual cycle. Trends Cell Biol. 33, 695–707 (2023).
Florez, M. A. et al. Clonal hematopoiesis: mutation-specific adaptation to environmental change. Cell Stem Cell 29, 882–904 (2022).
Sano, S. et al. JAK2V617F-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic Transl. Sci. 4, 684–697 (2019).
Díez-Díez, M. et al. Unidirectional association of clonal hematopoiesis with atherosclerosis development. Nat. Med. 30, 2857–2866 (2024).
Zhang, C. R. C. et al. Inflammatory cytokines promote clonal hematopoiesis with specific mutations in ulcerative colitis patients. Exp. Hematol. 80, 36–41.e33 (2019).
Pershad, Y. et al. Correlates and consequences of clonal hematopoiesis expansion rate: a 16-year longitudinal study of 6976 women. Blood 146, 1078–1087 (2025).
Sano, S. et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J. Am. Coll. Cardiol. 71, 875–886 (2018).
Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021).
Rauch, P. J. et al. Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypes. Nat. Cardiovasc. Res. 2, 805–818 (2023).
Caiado, F. & Manz, M. G. IL-1 in aging and pathologies of hematopoietic stem cells. Blood 144, 368–377 (2024).
McClatchy, J. et al. Clonal hematopoiesis related TET2 loss-of-function impedes IL1β-mediated epigenetic reprogramming in hematopoietic stem and progenitor cells. Nat. Commun. 14, 8102 (2023).
Pietras, E. M. et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat. Cell Biol. 18, 607–618 (2016).
Zuriaga, M. A. et al. Colchicine prevents accelerated atherosclerosis in TET2-mutant clonal haematopoiesis. Eur. Heart J. 45, 4601–4615 (2024).
Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
Svensson, E. C. et al. TET2-driven clonal hematopoiesis and response to canakinumab. An exploratory analysis of the CANTOS randomized clinical trial. JAMA Cardiol. 7, 521–528 (2022).
Nagai, Y. et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 24, 801–812 (2006).
Takizawa, H. et al. Pathogen-induced TLR4-TRIF innate immune signaling in hematopoietic stem cells promotes proliferation but reduces competitive fitness. Cell Stem Cell 21, 225–240.e5 (2017).
Chavakis, T., Mitroulis, I. & Hajishengallis, G. Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. Nat. Immunol. 20, 802–811 (2019).
Manz, M. G. & Boettcher, S. Emergency granulopoiesis. Nat. Rev. Immunol. 14, 302–314 (2014).
Swann, J. W., Olson, O. C. & Passegue, E. Made to order: emergency myelopoiesis and demand-adapted innate immune cell production. Nat. Rev. Immunol. 24, 596–613 (2024).
Zhao, J., Ghimire, A. & Liesveld, J. Marrow failure and aging: the role of “inflammaging”. Best Pract. Res. Clin. Haematol. 34, 101283 (2021).
Bogeska, R. et al. Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. Cell Stem Cell 29, 1273–1284.e8 (2022).
Rundberg Nilsson, A., Soneji, S., Adolfsson, S., Bryder, D. & Pronk, C. J. Human and murine hematopoietic stem cell aging is associated with functional impairments and intrinsic megakaryocytic/erythroid bias. PLoS ONE 11, e0158369 (2016).
Pang, W. W. et al. Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age. Proc. Natl Acad. Sci. USA 108, 20012–20017 (2011).
Geiger, H., de Haan, G. & Florian, M. C. The ageing haematopoietic stem cell compartment. Nat. Rev. Immunol. 13, 376–389 (2013).
Liang, Y., Van Zant, G. & Szilvassy, S. J. Effects of aging on the homing and engraftment of murine hematopoietic stem and progenitor cells. Blood 106, 1479–1487 (2005).
Caiado, F., Pietras, E. M. & Manz, M. G. Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection. J. Exp. Med. 218, e20201541 (2021).
Chen, C., Liu, Y., Liu, Y. & Zheng, P. mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells. Sci. Signal. 2, ra75 (2009).
Ho, T. T. et al. Autophagy maintains the metabolism and function of young and old stem cells. Nature 543, 205–210 (2017).
Rossi, D. J. et al. Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447, 725–729 (2007).
Rübe, C. E. et al. Accumulation of DNA damage in hematopoietic stem and progenitor cells during human aging. PLoS ONE 6, e17487 (2011).
Gutierrez-Martinez, P. et al. Diminished apoptotic priming and ATM signalling confer a survival advantage onto aged haematopoietic stem cells in response to DNA damage. Nat. Cell Biol. 20, 413–421 (2018).
Chambers, S. M. et al. Aging hematopoietic stem cells decline in function and exhibit epigenetic dysregulation. PLoS Biol. 5, e201 (2007).
Sun, D. et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell 14, 673–688 (2014).
Steensma, D. P. Clinical implications of clonal hematopoiesis. Mayo Clin. Proc. 93, 1122–1130 (2018).
Bick, A. G. et al. Inherited causes of clonal haematopoiesis in 97,691 whole genomes. Nature 586, 763–768 (2020).
Watson, C. J. et al. The evolutionary dynamics and fitness landscape of clonal hematopoiesis. Science 367, 1449–1454 (2020).
van Zeventer, I. A. et al. Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years. Blood Adv. 5, 2115–2122 (2021).
Marnell, C. S., Bick, A. & Natarajan, P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J. Mol. Cell Cardiol. 161, 98–105 (2021).
Young, A. L., Challen, G. A., Birmann, B. M. & Druley, T. E. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat. Commun. 7, 12484 (2016).
Assmus, B. et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A– and TET2-driver gene mutations. Eur. Heart J. 42, 257–265 (2020).
Mistry, J. J. et al. Mesenchymal stromal cell senescence induced by Dnmt3a-mutant hematopoietic cells is a targetable mechanism driving clonal hematopoiesis and initiation of hematologic malignancy. Preprint at bioRxiv https://doi.org/10.1101/2024.03.28.587254 (2024).
Hinds, D. A. et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood 128, 1121–1128 (2016).
Zink, F. et al. Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly. Blood 130, 742–752 (2017).
Weinstock, J. S. et al. Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis. Nature 616, 755–763 (2023). Zink et al. (2017) and Weinstock et al. (2023) identified inherited polymorphic loci that influence the aquisition of CHIP mutations, with the latter mechanistically showing how TCL1A rs2887399 affects the growth of different CHIP-mutant HSC clones.
Alagpulinsa, D. A., Toribio, M. P., Alhallak, I. & Shmookler Reis, R. J. Advances in understanding the molecular basis of clonal hematopoiesis. Trends Mol. Med. 28, 360–377 (2022).
Bhattacharya, R. et al. Association of diet quality with prevalence of clonal hematopoiesis and adverse cardiovascular events. JAMA Cardiol. 6, 1069–1077 (2021).
Haring, B. et al. Healthy lifestyle and clonal hematopoiesis of indeterminate potential: results from the Women’s Health Initiative. J. Am. Heart Assoc. 10, e018789 (2021).
Pasupuleti, S. K. et al. Obesity-induced inflammation exacerbates clonal hematopoiesis. J. Clin. Invest. 133, e163968 (2023).
Kar, S. P. et al. Genome-wide analyses of 200,453 individuals yield new insights into the causes and consequences of clonal hematopoiesis. Nat. Genet. 54, 1155–1166 (2022).
Coombs, C. C. et al. Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes. Cell Stem Cell 21, 374–382.e4 (2017).
Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Gen. 52, 1219–1226 (2020).
Kahn, J. D. et al. PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells. Blood 132, 1095–1105 (2018).
Boettcher, S. et al. A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies. Science 365, 599–604 (2019).
Dawoud, A. A. Z., Tapper, W. J. & Cross, N. C. P. Clonal myelopoiesis in the UK Biobank cohort: ASXL1 mutations are strongly associated with smoking. Leukemia 34, 2660–2672 (2020).
Ramanathan, G. et al. Cigarette smoke stimulates clonal expansion of Jak2V617F and Tet2−/− cells. Front. Oncol. 13, 1210528 (2023).
Caliri, A. W., Tommasi, S. & Besaratinia, A. Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer. Mutat. Res. Rev. Mutat. Res. 787, 108365 (2021).
Zioni, N. et al. Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis. Nat. Commun. 14, 2070 (2023).
Mistry, S. D. et al. Sex hormones are negatively associated with vertebral bone marrow fat. Bone 108, 20–24 (2018).
Elbaz, A., Rivas, D. & Duque, G. Effect of estrogens on bone marrow adipogenesis and Sirt1 in aging C57BL/6J mice. Biogerontology 10, 747–755 (2009).
Syed, F. A. et al. Effects of estrogen therapy on bone marrow adipocytes in postmenopausal osteoporotic women. Osteoporos. Int. 19, 1323–1330 (2008).
Andersson-Assarsson, J. C. et al. Evolution of age-related mutation-driven clonal haematopoiesis over 20 years is associated with metabolic dysfunction in obesity. eBioMedicine 92, 104621 (2023).
Lautenbach, A. et al. Long-term improvement of chronic low-grade inflammation after bariatric surgery. Obes. Surg. 31, 2913–2920 (2021).
Zhang, X., Sejas, D. P., Qiu, Y., Williams, D. A. & Pang, Q. Inflammatory ROS promote and cooperate with the Fanconi anemia mutation for hematopoietic senescence. J. Cell Sci. 120, 1572–1583 (2007).
Shao, L. et al. Reactive oxygen species and hematopoietic stem cell senescence. Int. J. Hematol. 94, 24–32 (2011).
Janzen, V. et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443, 421–426 (2006).
Ito, K. et al. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat. Med. 12, 446–451 (2006).
Pietras, E. M. et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J. Exp. Med. 211, 245–262 (2014).
Jacobsen, S. E. W. & Nerlov, C. Haematopoiesis in the era of advanced single-cell technologies. Nat. Cell Biol. 21, 2–8 (2019).
Chavez, J. S. et al. PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. J. Exp. Med. 218, e20201169 (2021).
Kaasinen, E. et al. Impact of constitutional TET2 haploinsufficiency on molecular and clinical phenotype in humans. Nat. Comm. 10, 1252 (2019).
Xia, P. et al. A circular RNA protects dormant hematopoietic stem cells from DNA sensor cGAS-mediated exhaustion. Immunity 48, 688–701.e7 (2018).
Jeong, M. et al. Loss of Dnmt3a immortalizes hematopoietic stem cells in vivo. Cell Rep. 23, 1–10 (2018).
Liao, M. et al. Aging-elevated inflammation promotes DNMT3A R878H-driven clonal hematopoiesis. Acta Pharm. Sin. B 12, 678–691 (2022).
SanMiguel, J. M. et al. Distinct tumor necrosis factor alpha receptors dictate stem cell fitness versus lineage output in Dnmt3a-mutant clonal hematopoiesis. Cancer Discov. 12, 2763–2773 (2022).
Zhang, C. R. et al. Txnip enhances fitness of Dnmt3a-mutant hematopoietic stem cells via p21. Blood Cancer Discov. 3, 220–239 (2022).
Venkatesulu, B. P. et al. Radiation-induced endothelial vascular injury: a review of possible mechanisms. JACC Basic Transl. Sci. 3, 563–572 (2018).
Abbuehl, J. P., Tatarova, Z., Held, W. & Huelsken, J. Long-term engraftment of primary bone marrow stromal cells repairs niche damage and improves hematopoietic stem cell transplantation. Cell Stem Cell 21, 241–255.e6 (2017).
Loberg, M. A. et al. Sequentially inducible mouse models reveal that Npm1 mutation causes malignant transformation of Dnmt3a-mutant clonal hematopoiesis. Leukemia 33, 1635–1649 (2019).
Hosseini, M. et al. Metformin reduces the competitive advantage of Dnmt3aR878H HSPCs. Nature 642, 421–430 (2025).
Gozdecka, M. et al. Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis. Nature 642, 431–441 (2025). Together with Hosseini et al. (2025), this research shows that the competitive expansion advantage of DNMT3A–mutant haematopoietic clones involves increased mitochondrial respiration and is counteracted by the anti-diabetic drug metformin.
Wang, Y. et al. Murine models of clonal hematopoiesis to assess mechanisms of cardiovascular disease. Cardiovasc. Res. 118, 1413–1432 (2022).
Jaiswal, S. et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N. Engl. J. Med. 377, 111–121 (2017).
Yalcinkaya, M. et al. BRCC3-mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in Tet2 clonal hematopoiesis. Circulation 148, 1764–1777 (2023).
Yura, Y. et al. The cancer therapy-related clonal hematopoiesis driver gene Ppm1d promotes inflammation and non-ischemic heart failure in mice. Circ. Res. 129, 684–698 (2021).
Liu, W. et al. Jak2V617F clonal hematopoiesis promotes arterial thrombosis via platelet activation and cross talk. Blood 143, 1539–1550 (2024). This study shows that Jak2V617F-driven CHIP promotes arterial thrombosis by combining evidence from an epidemiological meta-analysis with elegant mechanistic studies in a relevant mouse model.
Shumliakivska, M. et al. DNMT3A clonal hematopoiesis-driver mutations induce cardiac fibrosis by paracrine activation of fibroblasts. Nat. Commun. 15, 606 (2024).
Potempa, J., Mydel, P. & Koziel, J. The case for periodontitis in the pathogenesis of rheumatoid arthritis. Nat. Rev. Rheumatol. 13, 606–620 (2017).
Hajishengallis, G. & Chavakis, T. Local and systemic mechanisms linking periodontal disease and inflammatory comorbidities. Nat. Rev. Immunol. 21, 426–440 (2021).
Agrawal, M. et al. TET2-mutant clonal hematopoiesis and risk of gout. Blood 140, 1094–1103 (2022).
Sano, S. et al. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ. Res. 123, 335–341 (2018).
Meisel, M. et al. Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host. Nature 557, 580–584 (2018).
Zhang, Q. et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. Nature 525, 389–393 (2015).
Cobo, I. et al. DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophages. Immunity 55, 1386–1401.e10 (2022).
Abplanalp, W. T. et al. Cell-intrinsic effects of clonal hematopoiesis in heart failure. Nat. Cardiovasc. Res. 2, 819–834 (2023).
Charles, J. F. et al. Inflammatory arthritis increases mouse osteoclast precursors with myeloid suppressor function. J. Clin. Invest. 122, 4592–4605 (2012).
Yamashita, M., Dellorusso, P. V., Olson, O. C. & Passegué, E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nat. Rev. Cancer 20, 365–382 (2020).
Kristinsson, S. Y. et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J. Clin. Oncol. 29, 2897–2903 (2011).
Weeks, L. D. et al. Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 139, 1246–1250 (2022).
Kleppe, M. et al. Somatic mutations in leukocytes infiltrating primary breast cancers. NPJ Breast Cancer 1, 15005 (2015).
Park, S. J. & Bejar, R. Clonal hematopoiesis in cancer. Exp. Hematol. 83, 105–112 (2020).
Ahmad, H., Jahn, N. & Jaiswal, S. Clonal hematopoiesis and Its impact on human health. Annu. Rev. Med. 74, 249–260 (2023).
Buttigieg, M. M., Vlasschaert, C., Bick, A. G., Vanner, R. J. & Rauh, M. J. Inflammatory reprogramming of the solid tumor microenvironment by infiltrating clonal hematopoiesis is associated with adverse outcomes. Cell Rep. Med. 6, 101989 (2025).
Park, M. D. et al. Hematopoietic aging promotes cancer by fueling IL-1α-driven emergency myelopoiesis. Science 386, eadn0327 (2024). This paper shows that inflammageing drives declined expression of DNMT3A (thus mimicking the impairing effect of CHIP mutations on DNMT3A function), resulting in increased IL-1α production and promotion of solid cancer growth.
Buscarlet, M. et al. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood 130, 753–762 (2017).
Frick, M. et al. Role of donor clonal hematopoiesis in allogeneic hematopoietic stem-cell transplantation. J. Clin. Oncol. 37, 375–385 (2019).
Fraietta, J. A. et al. Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature 558, 307–312 (2018).
Bouzid, H. et al. Clonal hematopoiesis is associated with protection from Alzheimer’s disease. Nat. Med. 29, 1662–1670 (2023).
Balmer, M. L. et al. Microbiota-derived compounds drive steady-state granulopoiesis via MyD88/TICAM signaling. J. Immunol. 193, 5273–5283 (2014).
Lee, S. et al. Bone marrow CX3CR1+ mononuclear cells relay a systemic microbiota signal to control hematopoietic progenitors in mice. Blood 134, 1312–1322 (2019).
Yan, H., Baldridge, M. T. & King, K. Y. Hematopoiesis and the bacterial microbiome. Blood 132, 559–564 (2018).
Lee, Y. S. et al. Microbiota-derived lactate promotes hematopoiesis and erythropoiesis by inducing stem cell factor production from leptin receptor+ niche cells. Exp. Mol. Med. 53, 1319–1331 (2021).
Hergott, C. B. et al. Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis. Blood 127, 2460–2471 (2016).
Thevaranjan, N. et al. Age-associated microbial dysbiosis promotes intestinal permeability, systemic inflammation, and macrophage dysfunction. Cell Host Microbe 21, 455–466.e4 (2017).
Man, A. L. et al. Age-associated modifications of intestinal permeability and innate immunity in human small intestine. Clin. Sci. 129, 515–527 (2015).
Zeng, H. et al. Antibiotic treatment ameliorates Ten-eleven translocation 2 (TET2) loss-of-function associated hematological malignancies. Cancer Lett. 467, 1–8 (2019).
Robertson, N. A. et al. Age-related clonal haemopoiesis is associated with increased epigenetic age. Curr. Biol. 29, R786–R787 (2019).
Nachun, D. et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell 20, e13366 (2021).
Horvath, S. & Raj, K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat. Rev. Genet. 19, 371–384 (2018).
Mack, T. M. et al. Epigenetic and proteomic signatures associate with clonal hematopoiesis expansion rate. Nat. Aging 4, 1043–1052 (2024). This study of 4,370 CHIP carriers has associated DNA methylation-based biological ageing with the CHIP clonal expansion rate.
Chen, B. H. et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. Aging 8, 1844–1865 (2016).
Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging 10, 573–591 (2018).
Dai, Y. J. et al. Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement. Proc. Natl Acad. Sci. USA 114, 5237–5242 (2017).
Sun, J. et al. SIRT1 activation disrupts maintenance of myelodysplastic syndrome stem and progenitor cells by restoring TET2 function. Cell Stem Cell 23, 355–369.e9 (2018).
Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170, 1079–1095.e20 (2017).
Hajishengallis, G., Li, X. & Chavakis, T. Immunometabolic control of hematopoiesis. Mol. Asp. Med. 77, 100923 (2021).
Lu, R. & Wang, G. G. Pharmacologic targeting of chromatin modulators as therapeutics of acute myeloid leukemia. Front. Oncol. 7, 241 (2017).
Fujino, T. et al. Mutant ASXL1 induces age-related expansion of phenotypic hematopoietic stem cells through activation of Akt/mTOR pathway. Nat. Commun. 12, 1826 (2021).
Luengo, A., Sullivan, L. B. & Heiden, M. G. V. Understanding the complex-I-ty of metformin action: limiting mitochondrial respiration to improve cancer therapy. BMC Biol. 12, 82 (2014).
Tang, Y. et al. Inhibition of JAK2 suppresses myelopoiesis and atherosclerosis in Apoe−/− mice. Cardiovasc. Drugs Ther. 34, 145–152 (2020).
Bick, A. G. et al. Genetic interleukin 6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation 141, 124–131 (2020).
Agathocleous, M. et al. Ascorbate regulates haematopoietic stem cell function and leukaemogenesis. Nature 549, 476–481 (2017).
Taira, A. et al. Vitamin C boosts DNA demethylation in TET2 germline mutation carriers. Clin. Epigenet. 15, 7 (2023).
Li, X. et al. Maladaptive innate immune training of myelopoiesis links inflammatory comorbidities. Cell 185, 1709–1727.e18 (2022).
Franceschi, C. et al. Immunobiography and the heterogeneity of immune responses in the elderly: a focus on inflammaging and trained immunity. Front. Immunol. 8, 982 (2017).
Avagyan, S. et al. Resistance to inflammation underlies enhanced fitness in clonal hematopoiesis. Science 374, 768–772 (2021).
Arimatsu, K. et al. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci. Rep. 4, 4828 (2014).
McHugh, D. & Gil, J. Senescence and aging: causes, consequences, and therapeutic avenues. J. Cell Biol. 217, 65–77 (2017).
Crouch, J., Shvedova, M., Thanapaul, R. J. R. S., Botchkarev, V. & Roh, D. Epigenetic regulation of cellular senescence. Cells 11, 672 (2022).
Sidler, C., Kovalchuk, O. & Kovalchuk, I. Epigenetic regulation of cellular senescence and aging. Front. Genet. 8, 138 (2017).
Pietras, E. M. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood 130, 1693–1698 (2017).
Matatall, K. A. et al. Chronic infection depletes hematopoietic stem cells through stress-induced terminal differentiation. Cell Rep. 17, 2584–2595 (2016).
Salminen, A., Ojala, J. & Kaarniranta, K. Apoptosis and aging: increased resistance to apoptosis enhances the aging process. Cell Mol. Life Sci. 68, 1021–1031 (2011).
Hopfner, K. P. & Hornung, V. Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).
Chapman, J., Fielder, E. & Passos, J. F. Mitochondrial dysfunction and cell senescence: deciphering a complex relationship. FEBS Lett. 593, 1566–1579 (2019).
Wang, Y., Schulte, B. A., LaRue, A. C., Ogawa, M. & Zhou, D. Total body irradiation selectively induces murine hematopoietic stem cell senescence. Blood 107, 358–366 (2006).
Wang, Y. et al. Total body irradiation causes residual bone marrow injury by induction of persistent oxidative stress in murine hematopoietic stem cells. Free Rad. Biol. Med. 48, 348–356 (2010).
Park, I.-k. et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302–305 (2003).